LexBlog IP

MAY 31, 2023

Supreme Court invalidated two of Amgen’s patents for its cholesterol drug, Repatha, making it more difficult for patentees to obtain broadly worded patents. [1] 1] The case – Amgen Inc. 1] The full text of Amgen Inc. In a unanimous decision published on May 18, 2023, the U.S. Sanofi et al.

Invention 52

Invention Art Inventor Patent 52

Patently-O

APRIL 21, 2022

The only IP centric case that has been granted certiorari is Andy Warhol Foundation for the Visual Arts, Inc. I have divided the pending cases into three general categories: Patentability: Eligibility under Section 101 : American Axle & Manufacturing, Inc. Apple Inc., and Ameranth, Inc. Olo, Inc. ,

Patent Law 82

Patent Law Law Patent Art 82

LexBlog IP

JUNE 2, 2022

Late last week, Regeneron Pharmaceuticals, Inc. filed an antitrust complaint against Amgen Inc. Regeneron alleges that “Amgen is engaged in a persistent exclusionary campaign to deny patients the life-saving benefits of [] Regeneron’s cholesterol-reducing medication, Praluent® (alirocumab).”

Marketing 40

Marketing Marketing Business Branding 40

Patently-O

MAY 1, 2023

Teva Pharmaceuticals USA, Inc. A skinny-label occurs when a generic drug company seeks approval for a drug with a label that omits the patented indications of the brand-name drug. Travel Sentry, Inc., In addition, the Supreme Court has yet to rule on the Amgen v. The held-over cases include: 1. GlaxoSmithKline LLC , No.

Patent 80

Patent Technology Patent Infringement Branding 80

LexBlog IP

DECEMBER 21, 2023

STELARA® (ustekinumab) Four months after Janssen Biotech, Inc. 10,961,307 (“the ’307 Patent”), directed to methods of treating ulcerative colitis with ustekinumab, Biocon Biologics Inc. Both patents are assigned to Regeneron Pharmaceuticals, Inc., Samsung has now advanced further than Apotex Inc.

Patent 52

Patent Reporting Settlement Intellectual Property 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

Amgen/Allergan). Amgen/Johnson & Johnson). Roche/Genentech). rituximab-arrx. December 17, 2020. January 2021. off ASP and 23.7% off WAC of Rituxan ® ; and 15.2% off WAC of Truxima ®. adalimumab-fkjp. July 6, 2020. No earlier than July 31, 2023 per settlement. Nyvepria ™. Neulasta ®. pegfilgrastim-apgf. June 10, 2020. Remicade ®.

Settlement 52

Settlement Litigation Marketing Marketing 52

Patently-O

FEBRUARY 24, 2022

Eligibility under Section 101 : American Axle & Manufacturing, Inc. Patreon, Inc., Daktronics, Inc., Daktronics, Inc., Appellate Standing for IPR Challenger : Apple Inc. This question ties the case directly to MedImmune, Inc. Genentech, Inc. , Facebook, Inc. Daktronics, Inc.

Patent Law 95

Patent Law Law Patent Litigation 95

Patently-O

NOVEMBER 29, 2023

The Federal Circuit rejected this argument based on dicta in Thryv, Inc. 23-491 This case arises from multiple patent infringement lawsuits filed by Realtime Data LLC (d/b/a IXO) against various technology companies, including Fortinet, Inc., Reduxio Systems, Inc., See Amgen, Inc. 112–98, pt. Fortinet, No.

Patent Law 73

Patent Law Law Patent Art 73

SpicyIP

DECEMBER 5, 2022

Livanova India Private Limited vs Godaddy.Com, Inc. & Levi Straus & Company vs. Sunil Yadav on 24 November, 2022 (Delhi District Court). Bennett, Coleman And Company Ltd. Levi Straus & Company vs Sh. Ajinomoto Co Inc vs Dattatrey Studios & Anr on 28 November, 2022 (Delhi High Court).

Trademark 105

Trademark Registering Trademarks Registration IP 105

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. For example, Amgen recently announced that it has Phase 3 studies under way to support interchangeability status for its adalimumab and ustekinumab biosimilars, Amjevita ™ and ABP 654, respectively. Neulasta ® (Amgen).

Litigation 52

Litigation Settlement Patent Marketing 52

LexBlog IP

OCTOBER 19, 2021

Eli Lilly and Company , Appeals 2020-1747, -1748, and -1750 (Fed. Sandoz Inc. , See, e.g., Juno Therapeutics, Inc. Kite Pharma, Inc. 26, 2021) (regarding claims to a chimeric antigen receptor (for a T cell) that includes any single-chain antibody fragments capable of binding any targets); Amgen Inc.

Invention 52

Invention Licensing Art Patent 52

Patently-O

DECEMBER 14, 2021

Eligibility : American Axle & Manufacturing, Inc. Apple Inc. , Dropbox, Inc. , The petition has received amicus support as has a parallel petition in Apple Inc. ” More Appellate Standing : A third PTAB related appellate standing case is Apple Inc. Genentech, Inc. , Neapco Holdings LLC , No.

Patent Law 86

Patent Law Law Patent Licensing 86